Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=4333434 for the full story.

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=4333431 for the full story.

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=4322733 for the full story.

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=4251260 for the full story.

NitroMed Reports Profit, But Warns Of Future Losses

NitroMed (NDAQ: NTMD) buyout offer from Archemix received some opposition from an activist hedge fund. Deerfield Partners said that the merger overvalues Archemix and contains numerous conflicts of interest. Moreover, Deerfield, which holds a 12% stake, offered to acquire the company for $0.50 a share, liquidate the company and distribute the proceeds to shareholders. This would represent a substantially higher value than the current offer on the table. The majority of NitroMed’s value can be found in its $17.8 million in cash, equivalents and short-term investments as of September 30th. The company also stands to get an additional $26.3 million from the pending sale of heart failure drug BilDil, which was approved for African-American patients in 2005 but never gained significant market share. Assuming these sales, NitroMed would have about $44[More...]

Nitromed Inc. (NASDAQ: NTMD) shares are trending higher towards the end of the trading session after the company announced a licensing agreement with Elan Corp. unit Elan Pharma International Ltd. to...

Read more

Astea International, Generex Biotechnology, NYSE Group, Applied Materials, Intuitive Surgical, Baidu.com